Hu Ying, Li Baolan, Song Changxing
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijng 101149, China.
Zhongguo Fei Ai Za Zhi. 2008 Oct 20;11(5):734-8. doi: 10.3779/j.issn.1009-3419.2008.05.010.
Angiogenesis is necessary in tumor progression and metastasis. Serum vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) are important factors in angiogenesis. Elevated levels of VEGF and MMP-9 were reported in lung cancer. The aim of this research is to study the dynamic changes of serum VEGF and MMP-9 levels in non-small cell lung cancer (NSCLC) patients who underwent surgery.
Serum VEGF and MMP-9 levels were determined in 57 patients with NSCLC who were undergoing surgery by ELISA (enzyme linked immunosorbent assay) method before operation and on postoperative day 1, 7, 14. At the same time 18 patients with pulmonary benign diseases treated by surgery were studied as the control. Thirty healthy volunteers served to define normal VEGF and MMP-9.
Preoperative serum VEGF levels (685.50 pg/mL) was significantly higher in the group of patients with NSCLC compared with the benign and healthy group (respectively: 160.90 pg/mL, 94.40 pg/mL) (P <0.01); Serum VEGF levels were elevated after surgery and the levels were 1055.60 pg/mL, 1533.90 pg/mL, 1882.10 pg/mL, respectively, on postoperative day 1, 7, 14 (P <0.01). 2 Preoperative serum MMP-9 level (84.48 ng/mL) was significantly higher in the group of patients with NSCLC compared with the benign and healthy group (respectively: 58.98 ng/mL and 42.94 ng/mL, P <0.01); Serum MMP-9 levels were elevated soon after surgery and the peak (282.99 ng/mL) was observed on postoperative day 1 in NSCLC. Then serum MMP-9 levels dropped (respectively: 221.14 ng/mL and 194.78 ng/mL on postoperative 7 and 14) (P <0.01).
Preoperative serum VEGF and MMP-9 levels were both significantly higher in the group of patients with NSCLC compared with the benign and healthy group. Perioperative serum VEGF and MMP-9 levels were both significantly elevated in patients with NSCLC.
血管生成在肿瘤进展和转移过程中是必需的。血清血管内皮生长因子(VEGF)和基质金属蛋白酶-9(MMP-9)是血管生成中的重要因子。据报道,肺癌患者血清中VEGF和MMP-9水平升高。本研究旨在探讨接受手术治疗的非小细胞肺癌(NSCLC)患者血清VEGF和MMP-9水平的动态变化。
采用酶联免疫吸附测定(ELISA)法,对57例接受手术治疗的NSCLC患者术前及术后第1、7、14天的血清VEGF和MMP-9水平进行检测。同时,选取18例接受手术治疗的肺部良性疾病患者作为对照。选取30名健康志愿者以确定VEGF和MMP-9的正常水平。
NSCLC患者术前血清VEGF水平(685.50 pg/mL)显著高于良性疾病组和健康组(分别为:160.90 pg/mL、94.40 pg/mL)(P<0.01);术后血清VEGF水平升高,术后第1、7、14天分别为1055.60 pg/mL、1533.90 pg/mL、1882.10 pg/mL(P<0.01)。②NSCLC患者术前血清MMP-9水平(84.48 ng/mL)显著高于良性疾病组和健康组(分别为:58.98 ng/mL和42.94 ng/mL,P<0.01);术后血清MMP-9水平迅速升高,NSCLC患者术后第1天达到峰值(282.99 ng/mL)。随后血清MMP-9水平下降(术后第7天和第14天分别为:221.14 ng/mL和194.78 ng/mL)(P<0.01)。
NSCLC患者术前血清VEGF和MMP-9水平均显著高于良性疾病组和健康组。NSCLC患者围手术期血清VEGF和MMP-9水平均显著升高。